<DOC>
	<DOC>NCT02013206</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy. One group, consisting of patients who have never smoked, will receive Tarceva 150 mg/day, and the other group, consisting of current/former smokers, will receive Tarceva 150 mg/day increasing to a maximum of 300 mg/day. The anticipated time on study treatment is 1-2 years.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; histologically documented advanced nonsmall cell lung cancer (stage IIIB/IV); Eastern Cooperative Oncology Group (ECOG) performance status 02; no previous chemotherapy. previous therapy which acts on Epidermal Growth Factor Receptor (EGFR) axis; clinical evidence of brain metastasis; any unstable systemic disease; unable to take oral medication; any significant ophthalmological abnormality.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>